Cardiometabolic Health and Inflammatory Resolution

Cardiometabolic Health and Inflammatory Resolution (Kardiometabol hälsa Och Inflammatorisk Resolution)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04256330

Acronym

REX

Enrollment

200

Registered

2020-02-05

Start date

2020-01-23

Completion date

2027-09-01

Last updated

2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Volunteers

Brief summary

The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) or obese (\>30.0 kg/m2).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

* Informed signed consent has been obtained from the volunteer. * The volunteer has a BMI greater than 18.5 kg/m2

Exclusion criteria

* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information. * An MD determines that the individual is on too many medications to participate * The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw. * The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts) * The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication. * The individual has some form of chronic inflammation. * The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin). * The individual uses immunosuppressive drugs (eg, methotrexate). * The individual regularly consumes fish oils (omega 3). * The individual has significant gastrointestinal problems. * The individual smokes or uses chewing tobacco. * The individual has been drinking alcohol two days before the study visit. * The individual has tattoos or body piercings on the forearms and / or the stomach that can affect the examination. * The individual does not follow instructions given in the research study.

Design outcomes

Primary

Measure	Time frame	Description
Inflammatory status	2027	The inflammatory status, defined as CRP levels and ability to respond to pro-resolving therapeutics, will be studied in all 6 groups

Countries

Sweden

Contacts

Primary ContactEmma Börgeson, PhD

emma.borgeson@wlab.gu.se+46313423833

Backup ContactPer-Anders Jansson, MD, PhD

Per-Anders.Jansson@wlab.gu.se+46313420000

Outcome results